Prospective, multicenter, double-blind, randomized, cross-over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidemia in children with persisting proteinuria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN06912061

Enrollment

Registered

2006-05-26

Start date

2005-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glomerular diseases with proteinuria Nutritional, Metabolic, Endocrine Proteinuria, hyperlipidemia

Interventions

Sevelamer versus placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged 2-18 years, with persisting proteinuria and hypercholesterolemia.

Exclusion criteria

Exclusion criteria: 1. Chronic renal insufficiency (glomerular filtration rate [GFR] <40 ml/min) 2. Genetic forms of hyperlipidemia 3. Hyperlipidemia due to other causes

Design outcomes

Primary

Measure	Time frame
Decrease in serum cholesterol	—

Secondary

Measure	Time frame
1. Decrease in other lipids 2. Markers of oxidative stress 3. Proteinuria	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026